4503 Astellas Pharma
- 1590.0
- +3.5+0.22%
Astellas Pharma News
Astellas Pharma: US Food and Drug Administration acknowledges that Astellas Pharma has re-submitted a biologics license application for zolbetuximab and sets a new date for action
Astellas Pharma: FDA accepts re-application for approval of zolbetuximab
Astellas Pharma: Notice of Convocation of the 19th Annual General Meeting of Shareholders
Astellas Pharma: Matters not included in issuance documents based on the 19th Annual General Meeting of Shareholders Act and Articles of Incorporation
Astellas Pharma: Notice of Convocation of the 19th Annual General Meeting of Shareholders (including shareholders' meeting materials)
Astellas Pharma: Independent Officer Notification Form
Astellas Pharma: Notice regarding the continuation of the performance-linked stock compensation system for Astellas Group executives in Japan and overseas
Astellas Pharma: Notice regarding the continuation of the performance-based stock compensation system
Astellas Pharma: Notice regarding the continuation of the performance-based stock compensation system
Astellas Pharma: Notice regarding the continuation of the performance-linked stock reward system and performance-linked stock issuance system for our group executives in Japan and overseas
Astellas Pharma: Presentation materials for the briefing session (2023)
Astellas Pharma: Supplementary Documents (FY2023)
Astellas Pharma: Financial Results (FY2023)
Astellas Pharma: Financial results briefing materials for the fiscal year ending March 2024
Astellas Pharma: Supplemental Financial Results for the Fiscal Year Ending March 2024
Astellas Pharma: Summary of financial results for the fiscal year ending March 31, 2024 [IFRS] (consolidated)
Astellas Pharma: Changes in the definition of core-based performance
Astellas Pharma: Change of directors
Astellas Pharma: Changing the definition of core base in financial results
Astellas Pharma: Changes in officers
Analysis
Price Target
No Data
